Exagen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XGN research report →
Range $8 – $11
Price Chart
About the company
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- CEO
- John Aballi
- IPO
- 2019
- Employees
- 216
- HQ
- Vista, CA, US
Get TickerSpark's AI analysis on XGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $92.10M
- P/E
- -5.00
- PEG
- -0.26
- P/S
- 1.34
- P/B
- 6.86
- EV/EBITDA
- -8.64
- Div Yield
- 0.00%
- Gross Margin
- 58.74%
- Op Margin
- -20.08%
- Net Margin
- -25.14%
- ROE
- -125.60%
- ROIC
- -32.53%
Latest fiscal year · YoY change
- Revenue
- $66.58M+19.7%
- Gross Profit
- $38.80M+17.2%
- Op Income
- $-14,070,000
- Net Income
- $-19,951,000-32.0%
- EPS
- $-0.93-12.0%
- OCF Growth
- -2.6%
- FCF Growth
- -3.4%
- 52W High
- $9.22
- 52W Low
- $2.59
- 50D MA
- $7.43
- 200D MA
- $5.13
- Beta
- 2.24
- RSI (14)
- 28
- Avg Volume
- 466.41K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Exagen said Q3 showed continued record-setting execution, with revenue up 7% to $18.4 million, ASP at a record $451, and management reiterating full-year revenue guidance of $72 million to $75 million.· November 10, 2026
- Q3 revenue was $18.4 million, up 7%, with year-to-date revenue up more than 11%.
- Trailing 12-month ASP reached a record $451, up $10 year over year, and gross margin was just under 59%.
- Volume grew 2% in the quarter despite tougher comps and normal second-half seasonality; ordering physicians increased 5%.
- Pharma Services revenue was over $900,000 in Q3 and $2.2 million year to date, up nearly 85% versus last year.
- Management reiterated 2026 revenue guidance of $72 million to $75 million and said myositis remains on track for an early-2027 launch.
Exagen reported third-quarter revenue of $18.4 million, up 7% year over year, with AVISE CTD test volume up 2% and ordering clinicians up 5%. Trailing 12-month ASP was $451, up $10 year over year, and gross margin was just under 59%, up about 40 basis points. Adjusted EBITDA loss was $1.9 million, flat versus last year, while year-to-date revenue was up more than 11% and adjusted EBITDA improved more than 30%. Pharma Services revenue was over $900,000 in Q3 and $2.2 million year to date, up nearly 85%. Management reiterated full-year 2026 revenue guidance of $72 million to $75 million, assuming high single-digit volume growth, mid-single-digit ASP growth versus the fourth-quarter 2025 exit rate, second-half seasonality, and a growing Pharma Services contribution.
John Aballi framed Q3 as evidence that Exagen’s strategy is working, emphasizing record third-quarter revenue, record ASP, improving sales productivity, and progress toward becoming an autoimmune platform rather than a single-product company. He highlighted strong customer feedback on the upcoming myositis launch, saying it was the top requested new test, and said the product should be differentiated by breadth, unique markers, and faster turnaround. His tone was confident and constructive, with repeated references to long-term execution, a stronger balance sheet, and the company’s ability to grow revenue while investing in innovation.
Jeffrey Black focused on the financial mechanics behind the quarter: revenue of $18.4 million, gross margin just under 59%, operating expenses of $15.2 million, and adjusted EBITDA loss of $1.9 million. He said non-GAAP operating expenses were $13.4 million, up about 6%, and cited about $800,000 collected from claims older than 360 days in Q3. On the balance sheet, he said cash and equivalents ended just over $28 million, with about $6.5 million added through the ATM and a post-quarter $5 million draw from the Perceptive facility bringing pro forma cash to just over $33 million. He also reiterated that the company targets ASP of at least 50% of Medicare reimbursement, or approximately $600 to $650 per test, and said the business can reach adjusted EBITDA breakeven at an $80 million annual revenue run rate with around 60% gross margin.
Analysts focused on the Q4 revenue range, the path back to double-digit growth, myositis commercialization, PAMA, and payer coverage. Management said the guide midpoint reflects expected high single-digit volume growth and low-to-mid-single-digit ASP growth, while John Aballi said the company expects double-digit revenue growth on an annual basis and sees myositis, territory expansion, and stronger physician adoption as key drivers. On PAMA, he said the PLA code stayed stable at $840, generic CPT codes could create low-single-digit blended headwinds if fully implemented, and revenue-cycle improvements should offset pressure over time. On myositis, he said the launch remains on track for early 2027, with a 17-marker profile, quantitative readouts, and an expected turnaround within a week; on payer coverage, he said systematic review work has opened doors with payers and helped advance discussions, including with Blue plans and through ALJ appeals.
The positive case from the call is that Exagen is still growing revenue, ASP, and physician adoption while expanding into new products and services. Management believes myositis can open a new growth leg, Pharma Services is scaling quickly, and reimbursement work continues to improve ASP over time. The company also ended the quarter with more cash and said it has runway to reach sustainable positive adjusted EBITDA and operating cash flow.
The main risks discussed were seasonality, tougher year-over-year volume comparisons, and possible reimbursement pressure from PAMA and generic code mix. Management also said myositis is not yet launched, its ramp is still being figured out, and further sales expansion will be measured rather than aggressive. Coverage progress with large payers remains uneven and longer-term, and management acknowledged that some revenue-cycle benefits can be lumpy quarter to quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 59.4%
- Shares Outstanding
- 25.51M
- Float Shares
- 15.16M
of shares held by institutions
57 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parkman Healthcare Partners LLC | 926.55K | ▲ 926.55K |
| Vanguard Group Inc | 790.01K | ▲ 56.19K |
| Wexford Capital LP | 759.84K | ▼ 33.02K |
| Nano Cap New Millennium Growth Fund L P | 700.00K | ▲ 25.00K |
| Vanguard Capital Management LLC | 623.91K | ▲ 11.07K |
| Mink Brook Asset Management LLC | 531.67K | ▲ 55.73K |
| First Eagle Investment Management, LLC | 516.10K | ▲ 209.13K |
| Silvercrest Asset Management Group LLC | 469.46K | ▼ 45.30K |
| Marshall Wace, Llp | 392.79K | ▲ 86.09K |
| Fourworld Capital Management LLC | 352.54K | ▼ 243.99K |
| Acadian Asset Management LLC | 311.48K | ▲ 1.40K |
| Schonfeld Strategic Advisors LLC | 310.09K | ▲ 310.09K |
Held by 30 ETFs
Biggest fund positions in XGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Chernett Jorey | sell | 109,436 |
| Nov 13, 26 | Chernett Jorey | sell | 58,068 |
| Nov 11, 26 | Chernett Jorey | buy | 71,315 |
| Nov 10, 26 | Chernett Jorey | buy | 7,085 |
| Nov 9, 26 | Chernett Jorey | buy | 8,500 |
| Nov 6, 26 | Chernett Jorey | sell | 11,265 |
| Jun 9, 26 | Nova Tina Susan | other | 56,200 |
| Oct 19, 26 | Chernett Jorey | buy | 14,000 |
| Oct 16, 26 | ABALLI JOHN | sell | 34,294 |
| Oct 16, 26 | Chernett Jorey | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XGN coverage
Recent articles, reports, and earnings notes.
No research on XGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XGN report →Exagen: Q3 Raises Questions About The Turnaround (Rating Downgrade)
seekingalpha.com · Nov 13
What Exagen (XGN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 10
Exagen Inc. Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
Exagen Inc. to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 29
Exagen to Announce Third Quarter Financial Results on November 10, 2026
globenewswire.com · Oct 27
Exagen (NASDAQ: XGN) owner buys 14,000 shares in new insider filing
defenseworld.net · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.